{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:25:04Z","timestamp":1791638704329,"version":"4.3.4"},"reference-count":41,"publisher":"Society of Nuclear Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,12,15]]},"published-print":{"date-parts":[[2026,5]]},"DOI":"10.2967\/jnumed.125.269933","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T17:10:13Z","timestamp":1769706613000},"page":"773-779","source":"Crossref","is-referenced-by-count":4,"title":["Development of an Optimized CXCR4-Targeting Theranostic Pair"],"prefix":"10.2967","volume":"67","author":[{"given":"Daniel","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Bloise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Colpo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Merkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Zeisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Shyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"B\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2026050105301237000_67.5.773.1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2000.17715.x"},{"key":"2026050105301237000_67.5.773.2","doi-asserted-by":"publisher","DOI":"10.1038\/84224"},{"key":"2026050105301237000_67.5.773.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.05.008"},{"key":"2026050105301237000_67.5.773.4","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.121806.154841"},{"key":"2026050105301237000_67.5.773.5","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3217"},{"key":"2026050105301237000_67.5.773.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3182"},{"key":"2026050105301237000_67.5.773.7","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.49"},{"key":"2026050105301237000_67.5.773.8","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.10.16"},{"key":"2026050105301237000_67.5.773.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.05.005"},{"key":"2026050105301237000_67.5.773.10","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.3390\/cancers13235920","article-title":"In vivo targeting of CXCR4\u2014new horizons","volume":"13","author":"Schottelius","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2026050105301237000_67.5.773.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.097733"},{"key":"2026050105301237000_67.5.773.12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.7150\/thno.13986","article-title":"68Ga-pentixafor-PET\/CT for imaging of chemokine receptor 4 expression in glioblastoma","volume":"6","author":"Lapa","year":"2016","journal-title":"Theranostics."},{"key":"2026050105301237000_67.5.773.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.151647"},{"key":"2026050105301237000_67.5.773.14","doi-asserted-by":"crossref","first-page":"567","DOI":"10.7150\/thno.48620","article-title":"CXCR4 PET imaging of mantle cell lymphoma using [68Ga]pentixafor: comparison with [18F]FDG-PET","volume":"11","author":"Mayerhoefer","year":"2021","journal-title":"Theranostics."},{"key":"2026050105301237000_67.5.773.15","doi-asserted-by":"publisher","DOI":"10.7150\/thno.19119"},{"key":"2026050105301237000_67.5.773.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.167361"},{"key":"2026050105301237000_67.5.773.17","doi-asserted-by":"publisher","DOI":"10.7150\/thno.45537"},{"key":"2026050105301237000_67.5.773.18","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0850"},{"key":"2026050105301237000_67.5.773.19","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1021\/acs.molpharmaceut.9b00808","article-title":"[68Ga]Ga\/[177Lu]Lu-BL01, a novel theranostic pair for targeting C-X-C chemokine receptor 4","volume":"16","author":"Lau","year":"2019","journal-title":"Mol Pharmaceutics."},{"key":"2026050105301237000_67.5.773.20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1021\/acs.molpharmaceut.0c00785","article-title":"High-contrast CXCR4-targeted 18F-PET imaging using a potent and selective antagonist","volume":"18","author":"Kwon","year":"2021","journal-title":"Mol Pharmaceutics."},{"key":"2026050105301237000_67.5.773.21","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-21-3284","article-title":"Targeting refractory mantle cell lymphoma for imaging and therapy using C-X-C chemokine receptor type 4 radioligands","volume":"28","author":"Kwon","year":"2022","journal-title":"Clin Cancer Res."},{"key":"2026050105301237000_67.5.773.22","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3390\/pharmaceutics14071502","article-title":"Reducing the kidney uptake of high contrast CXCR4 PET imaging agents via linker modifications","volume":"14","author":"Kwon","year":"2022","journal-title":"Pharmaceutics."},{"key":"2026050105301237000_67.5.773.23","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11523-016-0434-9","article-title":"A randomized, open-label phase 2 study of the CXCR4 inhibitor LY2510924 in combination with sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma (RCC)","volume":"11","author":"Hainsworth","year":"2016","journal-title":"Target Oncol."},{"key":"2026050105301237000_67.5.773.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.12.020"},{"key":"2026050105301237000_67.5.773.25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-7-123"},{"key":"2026050105301237000_67.5.773.26","doi-asserted-by":"publisher","DOI":"10.1002\/anie.200351024"},{"key":"2026050105301237000_67.5.773.27","doi-asserted-by":"crossref","first-page":"9641","DOI":"10.1021\/acs.jmedchem.7b01062","article-title":"Structure\u2013activity relationships and biological characterization of a novel, potent, and serum stable C-X-C chemokine receptor type 4 (CXCR4) antagonist","volume":"60","author":"Di Maro","year":"2017","journal-title":"J Med Chem."},{"key":"2026050105301237000_67.5.773.28","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.201300228"},{"key":"2026050105301237000_67.5.773.29","doi-asserted-by":"crossref","first-page":"94619","DOI":"10.18632\/oncotarget.21816","article-title":"Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587","volume":"8","author":"Peng","year":"2017","journal-title":"Oncotarget."},{"key":"2026050105301237000_67.5.773.30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13550-019-0545-2","article-title":"Validation of [125I]CPCR4.3 as an investigative tool for the sensitive and specific detection of hCXCR4 and mCXCR4 expression in\u00a0vitro and in\u00a0vivo","volume":"9","author":"Schottelius","year":"2019","journal-title":"EJNMMI Res."},{"key":"2026050105301237000_67.5.773.31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1053\/j.semnuclmed.2023.09.002","article-title":"Advances in PET Imaging of the CXCR4 receptor: [68Ga]Ga-pentixafor","volume":"54","author":"Lindenberg","year":"2024","journal-title":"Semin Nucl Med."},{"key":"2026050105301237000_67.5.773.32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MNM.0000000000001806","article-title":"Diagnostic value of [68Ga]Ga-pentixafor PET\/CT in malignant melanoma: a pilot study","volume":"45","author":"Manafi-Farid","year":"2024","journal-title":"Nucl Med Commun."},{"key":"2026050105301237000_67.5.773.33","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3390\/diagnostics14131375","article-title":"Chemokine receptor-4 targeted PET\/CT imaging with 68Ga-pentixafor in head and neck cancer: a comparison with 18F-FDG and CXCR4 immunohistochemistry","volume":"14","author":"Hadebe","year":"2024","journal-title":"Diagnostics."},{"key":"2026050105301237000_67.5.773.34","first-page":"208","article-title":"Diagnostic efficacy of C-X-C motif chemokine receptor 4-directed PET\/CT in newly diagnosed head and neck squamous cell carcinoma: a head-to-head comparison with [18F]FDG","volume":"13","author":"Zhi","year":"2023","journal-title":"Am J Nucl Med Mol Imaging."},{"key":"2026050105301237000_67.5.773.35","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13550-018-0442-0","article-title":"PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma","volume":"8","author":"Vag","year":"2018","journal-title":"EJNMMI Res."},{"key":"2026050105301237000_67.5.773.36","doi-asserted-by":"publisher","DOI":"10.7150\/thno.12303"},{"key":"2026050105301237000_67.5.773.37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-791392"},{"key":"2026050105301237000_67.5.773.38","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24797"},{"key":"2026050105301237000_67.5.773.39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40164-019-0126-0","article-title":"Mantle cell lymphoma and its management: where are we now?","volume":"8","author":"Ladha","year":"2019","journal-title":"Exp Hematol Oncol."},{"key":"2026050105301237000_67.5.773.40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3015"},{"key":"2026050105301237000_67.5.773.41","first-page":"3276925","article-title":"Identification of CXCR4 upregulation in diffuse large B-cell lymphoma associated with prognostic significance and clinicopathological characteristics","volume":"2022","author":"Zhang","year":"2022","journal-title":"Dis Markers."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.269933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:31:16Z","timestamp":1777638676000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.269933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,1]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.2967\/jnumed.125.269933"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.269933","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}